Last reviewed 2026-04-20 · How we verify

Diteftin (FURSULTIAMINE)

FDA-approved active Small molecule Quality 6/100

Diteftin (generic name: FURSULTIAMINE) is a fursultiamine drug. It is currently FDA-approved.

Fursultiamine (Diteftin) is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it maintains a competitive edge through its current market presence and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	FURSULTIAMINE
Drug class	fursultiamine
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Diteftin CI brief — competitive landscape report
Diteftin updates RSS · CI watch RSS

Frequently asked questions about Diteftin

What is Diteftin?

Diteftin (FURSULTIAMINE) is a fursultiamine drug.

What is the generic name of Diteftin?

FURSULTIAMINE is the generic (nonproprietary) name of Diteftin.

What drug class is Diteftin in?

Diteftin belongs to the fursultiamine class. See all fursultiamine drugs at /class/fursultiamine.

What development phase is Diteftin in?

Diteftin is FDA-approved (marketed).

Drug class: All fursultiamine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing